Q1 FY27 Results: Revenue up 30 percent, PAT more than doubles YoY
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venus Remedies Q1 FY27 standalone revenue grew about 30 percent YoY to INR 178.80 Cr (vs INR 137.13 Cr). Net profit more than doubled to INR 25.53 Cr from INR 11.70 Cr. EBITDA rose to INR 39.11 Cr versus INR 20.66 Cr. Board also approved revisions to the Memorandum of Association, to be placed before members at the 37th AGM. Auditor flagged an emphasis of matter on about INR 28.60 Cr share application money pending at wholly owned German subsidiary Venus Pharma GmbH, which faces financial challenges, with parent company support pledged during restructuring.
Strong quarter with doubled profits and healthy revenue growth. German subsidiary risk flagged but management has committed financial and operational support.